Among CRC patients, 38% had serum HSP60 levels below this limit, suggesting that the marker may benefit from an assay method with increased analytical sensitivity that is able to quantify in the dozens of pg·mL−1 range. The gene discussed is HSPD1; the disease is colorectal carcinoma.